IN2013CN09704A - - Google Patents

Info

Publication number
IN2013CN09704A
IN2013CN09704A IN9704CHN2013A IN2013CN09704A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A IN 9704CHN2013 A IN9704CHN2013 A IN 9704CHN2013A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A
Authority
IN
India
Prior art keywords
mirabegron
preparation
form crystal
amorphous
aspects
Prior art date
Application number
Other languages
English (en)
Inventor
Vishweshwar Peddy
Rajesham Boge
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Priority to IN9704CHN2013 priority Critical patent/IN2013CN09704A/en
Publication of IN2013CN09704A publication Critical patent/IN2013CN09704A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
IN9704CHN2013 2011-05-18 2012-05-17 IN2013CN09704A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN9704CHN2013 IN2013CN09704A (zh) 2011-05-18 2012-05-17

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1678CH2011 2011-05-18
US201161502911P 2011-06-30 2011-06-30
PCT/IN2012/000356 WO2012156998A2 (en) 2011-05-18 2012-05-17 Amorphous mirabegron and processes for crystal forms of mirabegron
IN9704CHN2013 IN2013CN09704A (zh) 2011-05-18 2012-05-17

Publications (1)

Publication Number Publication Date
IN2013CN09704A true IN2013CN09704A (zh) 2015-07-03

Family

ID=47177412

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9704CHN2013 IN2013CN09704A (zh) 2011-05-18 2012-05-17

Country Status (4)

Country Link
US (1) US9283210B2 (zh)
EP (1) EP2709993A4 (zh)
IN (1) IN2013CN09704A (zh)
WO (1) WO2012156998A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655885B2 (en) * 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (it) 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
US20170291882A1 (en) * 2014-10-01 2017-10-12 Apotex Inc. Solid Forms of Mirabegron
US9981927B2 (en) 2015-02-02 2018-05-29 Lupin Limited Process for preparation of polymorphic form of Mirabegron
US10253005B2 (en) * 2015-05-11 2019-04-09 Aurobindo Pharma Ltd. Process for the preparation of Mirabegron alpha-form crystals
JP6618736B2 (ja) * 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
FR3043555B1 (fr) * 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) Mirabegron pour le traitement de maladies retiniennes
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR101928987B1 (ko) * 2018-08-28 2018-12-13 (주) 성운파마코피아 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
CN110590699B (zh) * 2019-09-29 2022-11-15 广东先强药业有限公司 一种米拉贝隆的精制方法
CN112745276B (zh) * 2019-10-31 2023-10-03 四川国为制药有限公司 一种米拉贝隆的结晶方法
US11583521B2 (en) * 2020-07-01 2023-02-21 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
CN114539182B (zh) * 2020-11-24 2024-08-09 威智医药股份有限公司 转晶溶剂及其应用和米拉贝隆α晶型的制备方法
KR102333167B1 (ko) 2021-05-26 2021-12-01 유니셀랩 주식회사 효율적이고 대량생산이 가능한 미라베그론 무정형 제조방법
CN113773274A (zh) * 2021-08-09 2021-12-10 石药集团中奇制药技术（石家庄）有限公司 一种米拉贝隆α晶型原料的重结晶方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3193706B2 (ja) 1997-10-17 2001-07-30 山之内製薬株式会社 アミド誘導体又はその塩
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
MXPA05004925A (es) * 2002-11-07 2005-08-18 Yamanouchi Pharma Co Ltd Remedio para vejiga hiperactiva que incluye derivado de anilida de acido acetico como el ingrediente activo.

Also Published As

Publication number Publication date
EP2709993A2 (en) 2014-03-26
US20140206729A1 (en) 2014-07-24
US9283210B2 (en) 2016-03-15
WO2012156998A2 (en) 2012-11-22
WO2012156998A3 (en) 2013-01-17
EP2709993A4 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
IN2013CN09704A (zh)
HK1196849A1 (zh) 用於產生有用代謝物的重組微生物
PL2744768T3 (pl) Sposób wytwarzania klinkieru zawierającego ternezyt
IN2015KN00262A (zh)
MX2015005891A (es) Formas polimórficas de suvorexant.
EP2669411A4 (en) SILICONE MELT CONTACT ELEMENT AND METHOD FOR THE PRODUCTION THEREOF, AND METHOD FOR THE PREPARATION OF CRYSTALLINE SILICON
PL2806745T3 (pl) Sposób wytwarzania kompozycji zawierającej aktywną folistatynę
PL2785701T3 (pl) Krystaliczna postać kabazytakselu i sposób jej otrzymywania
SG11201402949RA (en) Process for producing nutrient composition
EA029539B8 (ru) Фармацевтическая композиция ситаглиптина
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IL229647A0 (en) A new process for the preparation of prostaglandin amides
ZA201404440B (en) Process for the preparation of travoprost
WO2014068586A3 (en) Solid oral compositions of tolvaptan
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
EP2732028A4 (en) COMPOSITIONS AND METHODS OF PREPARING ISOPRENE
EP2671847A4 (en) Process for manufacture of phosphor-dispersed glass, and phosphor-dispersed glass
EP2589662A4 (en) Process for production of useful substance
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
IN2014DN09451A (zh)
WO2014102759A3 (en) Process for the preparation of dasatinib and its intermediates
MX2014009015A (es) Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma.
HUP1100177A2 (en) Recycled composition and process for preparation of it and production of regenarated, vulcanised gum
IN2013CH05282A (zh)
EP2694621B8 (en) Methods for the production of fuel